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Abstract
Quercetin is a dietary flavonoid which exerts vasodilator, antiplatelet and
antiproliferative effects and reduces blood pressure, oxidative status and end-organ
damage in humans and animal models of systemic hypertension. We hypothesized
that oral quercetin treatment might be protective in a rat model of pulmonary arterial
hypertension. Three weeks after injection of monocrotaline, quercetin (10 mg/kg/d
per os) or vehicle was administered for 10 days to adult Wistar rats. Quercetin
significantly reduced mortality. In surviving animals, quercetin decreased
pulmonary arterial pressure, right ventricular hypertrophy and muscularization of
small pulmonary arteries. Classic biomarkers of pulmonary arterial hypertension
such as the downregulated expression of lung BMPR2, Kv1.5, Kv2.1, upregulated
survivin, endothelial dysfunction and hyperresponsiveness to 5-HT were unaffected
by quercetin. Quercetin significantly restored the decrease in Kv currents, the
upregulation of 5-HT2A receptors and reduced the Akt and S6 phosphorylation. In
vitro, quercetin induced pulmonary artery vasodilator effects, inhibited pulmonary
artery smooth muscle cell proliferation and induced apoptosis. In conclusion,
quercetin is partially protective in this rat model of PAH. It delayed mortality by
lowering PAP, RVH and vascular remodeling. Quercetin exerted effective
vasodilator effects in isolated PA, inhibited cell proliferation and induced apoptosis
in PASMCs. These effects were associated with decreased 5-HT2A receptor
expression and Akt and S6 phosphorylation and partially restored Kv currents.
Therefore, quercetin could be useful in the treatment of PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a rare disease characterized by elevated
pulmonary arterial pressure (PAP) due to increased vasoconstriction, remodeling
of the pulmonary microvasculature and thrombosis, leading to right ventricular
hypertrophy (RVH) and premature death [1]. PAH exhibits a complex
pathophysiology, unlikely to be explained by a single factor [2, 3]. Mutations in
the bone morphogenetic protein receptor type 2 (BMPR2) are responsible for
many heritable forms of PAH and downregulation of its expression underlie many
idiopathic and secondary forms of PAH [4, 5]. BMPR2 dysfunction leads to
increased transforming growth factor-b (TGF-b) signaling [6] leading to
activation of proliferative pathways including the mitogen activated protein
kinases (MAPKs) pathway, the phosphatidylinositide 3-kinases, serine/threonine
kinase Akt and the mammalian target of rapamycin (PI3K/Akt/mTOR) pathway
and the antiapoptotic protein survivin. Inactivation, downregulation or gene
polymorphisms of voltage-gated potassium channels (KV) [7], hyperresponsive-
ness to 5-HT [8] and loss of NO bioavailability and the subsequent endothelial
dysfunction have also been implicated in the pathophysiology of PAH [9].
Although no cure exists for PAH, the understanding of the pathophysiological
mechanisms has led to the development of therapies which improve symptoms
and slow the progression of the disease [10].
Quercetin is a natural flavonoid regularly consumed in the diet in the form of
fruits, vegetables, nuts and derived products such as wine and chocolate.
Prospective studies have shown an inverse correlation between dietary flavonoid
intake and mortality from coronary heart disease [11]. Several studies using
various animal models provide support for the observed protective effects of
dietary flavonoids with respect to cardiovascular diseases [12]. Quercetin exerts
systemic, coronary and pulmonary artery vasodilatation and antiaggregant effects
in vitro [13, 14, 15], and reduces blood pressure, oxidative status and end-organ
damage in animal models of hypertension [16].
We hypothesized that quercetin could be effective in reversing PAH. Therefore,
we tested the efficacy of oral quercetin in a rat model of PAH generated by a single
injection of the plant toxin monocrotaline. This model reproduces several key
aspects of PAH, including elevated PAP, RVH, premature death, vascular
remodeling, oxidative stress, endothelial dysfunction, and alteration in the
BMPR2, KV and 5-HT pathways.
Methods
Ethics statement
The investigation conforms with the Directive 2010/63/EU of the European
Parliament and the procedures were approved by our institutional Ethical
Committee (Comité de Experimentación Animal de la Universidad Complutense
de Madrid). All efforts were made to minimize suffering. Animals were monitored
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daily and eventually sacrificed by deep anesthesia followed by decapitation before
the predefined duration of the treatment if death, due to right heart failure, could
be anticipated based on immobility and general state of the animal.
Animals and treatments
The study protocol is shown in Figure 1. Male Wistar rats of 225–250 g of body
weight (BW) from Harlan Iberica (Barcelona, Spain) were maintained in the
general animal facility of Universidad Complutense (ANUC), five per cage, at a
constant temperature (24¡1 C̊), with a 12-hour light/dark cycle, on a standard
chow and water ad libitum. Animals were randomly divided into a control and a
pulmonary hypertensive group. Pulmonary hypertension was induced by a single
intraperitoneal (i.p.) injection of 60 mg kg21 monocrotaline (control animals
were injected with saline). Twenty one days after monocrotaline injection, i.e.
after the animals have developed marked increases in PAP, rats from both groups
were further randomly assigned to vehicle or quercetin treatment (10 mg kg21
once daily 9:00–11:00 AM, dissolved in 1 mL of 1% methylcellulose) by gastric
gavage for an additional period of 11 days. This dose has widely demonstrated to
be effective in systemic hypertension in rats [16] and the treatment period was
chosen because in the 4–6th week is the period of maximal worsening of the
disease and higher mortality in this model. The study was run in three batches; all
groups were followed in parallel in the first two and the two monocrotaline
Figure 1. Quercetin increases survival. (A) Study protocol. Numbers in parenthesis indicate the number of
rats which started and finished each period. The numbers at the far right indicate the number of rats in which
pulmonary arterial pressure could be recorded; the missing animals in the monocrotaline (MCT) group died
during the anesthesia or surgery. (B) Kaplan-Meier analysis of survival in rats treated with monocrotaline and
monocrotaline plus quercetin (Quer). * indicates P,0.05.
doi:10.1371/journal.pone.0114492.g001
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groups in the last one. The number of rats in each group was adjusted to reach a
similar number of surviving rats in all groups at the end of the treatment based on
the expected and actual mortality.
Pressure measurements
Twenty-four h after the last administration of quercetin or vehicle rats were
anaesthetized i.p. with 80 mg kg21 ketamine plus 8 mg kg21 xylazine and
ventilated with room air (tidal volume 9 ml kg21, 60 breaths min21, positive end-
expiratory pressure 2 cm H2O). Right ventricular systolic and diastolic pressure
(RVSP, RVDP) and systolic, diastolic and mean pulmonary arterial pressures
(SPAP, DPAP and MPAP) were then measured in open-chest rats with a pressure
transducer via a catheter advanced through the right ventricle into the PA. It
should be noted that the pressure and heart rate values obtained in anaesthetized
open-chest rats may represent an underestimation of the values in closed-chest
conscious animals. At the end of the recordings, hearts were excised and the right
ventricle (RV) and the left ventricle plus septum (LV+S) were carefully dissected
and weighed. The ratio RV/BW and the Fulton Index [RV/(LV+S)] were
calculated to assess the right ventricular hypertrophy.
Lung histology
The right lung was inflated in situ with formol saline through the right bronchus
and embedded in paraffin. Lung sections were stained with haematoxylin and
eosin and Masson trichrome techniques and examined by light microscopy, and
elastin was visualized by its green autofluorescence. Small arteries (25–100 mm
outer diameter) were analysed in a blinded fashion and categorized as muscular,
partially muscular or nonmuscular as previously described [17].
Vascular reactivity
Intrapulmonary artery rings (2–3 mm long, ,0.5–0.8 mm internal diameter)
were dissected and mounted in Krebs solution bubbled with 21%O2 and 5% CO2
under 0.75 g of resting tension in organ chambers as previously described [18].
After equilibration, arterial rings from the four animal groups were firstly
stimulated with KCl (80 mM). Thereafter, preparations were washed and after
45 min were contracted by 1027M phenylephrine, and concentration–response
curves to acetylcholine (10292361024 M) were performed by cumulative
addition. In different rings a concentration–response curves to serotonin
(36102821024 M) were performed by cumulative addition.
KV current recordings
For smooth muscle cells isolation, endothelium-denuded PA were cut into small
segments (262 mm) and placed in Ca2+-free physiological salt solution
containing (in mg/ml) 1 papain, 0.8 dithiothreitol and 0.7 albumin. Tissues were
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incubated in this solution at 4 C̊ for 10 minutes and then agitated for 7 minutes at
37 C̊. Afterwards, tissues were washed in Ca2+-free physiological salt solution and
disaggregated using a wide bore, smooth-tipped pipette. Cells were stored at 4 C̊
and used within 8 h of isolation. Membrane currents were recorded using the
whole-cell configuration of the patch clamp technique as previously described
[19]. Membrane potential (Em) was measured under current clamp mode.
Real time RT-PCR
Total RNA was isolated and purified from whole lung homogenates using RNeasy
Mini kit (Qiagen, Hilden, Germany). Real-time PCR was performed using a
Taqman system (Roche Diagnostics, Mannheim, Germany) in the Genomic Unit
of Universidad Complutense de Madrid. Specific primers were designed for Kv1.5
(sense 59-GGAAGAACAAGGCAACCAGA-39, antisense 59-
AGCTGACCTTCCGTTGACC-39), iNOS (sense 59-
TTGGAGTTCACCCAGTTGTG-39, antisense 59-ACATCGAAGCGGCCATAG-
39), eNOS (sense 59-GGTATTTGATGCTCGGGACT-39, antisense 59-
TGTGGTTACAGATGTAGGTGAACA-39), caveolin-1 (sense 59-
GGGCATGAAGGCAGGTTAT 239, antisense 59-
AGTGAGGACAGCAACCAACTC 239), BMPR2 (sense 59-
CGGGCAGGATAAATCAGGA-39, antisense5’-
CAGGAAAGTAAATTCGGGTGA-39), 5HT2A (sense 59-
CTGCTCAATGTGTTTGTCTGG-39, antisense 59-
GAACAACGTATATACCAGTGGATTGA-39) and b-actin (sense 59-
GCCCTAGACTTCGAGCAAGA-39, antisense 59-
TCAGGCAGCTCATAGCTCTTC-39). Survivin, Kv 2.1, Kv 7.1 and Kv 7.5
expression was analyzed using commercial primers from Applied Biosystems. The
data were corrected by the expression of b-actin and expressed as relative
expression of target genes in control animals using the delta-delta Ct method
(RQ).
Western blotting analysis
Lung homogenates were run on a sodium dodecyl sulphate-polyacrilamide
electrophoresis. Proteins were transferred to polyvinylidene difluoride mem-
branes, incubated with primary antibodies against survivin, ERK1/2, p38, Akt, S6
or the phosphorylated forms of ERK1/2, p38, Akt and S6 240–244 (all from Cell
Signalling Technology, Danvers, MA, except the anti-survivin and the anti-p-p38
antibodies from Santa Cruz, Dallas) and then with the secondary peroxidase
conjugated antibodies. Antibody binding was detected by an ECL system
(Amersham Pharmacia Biotech, Amersham, UK) and densitometric analysis was
performed using Scion Image-Release Beta 4.02 software Samples were re-probed
for expression of smooth muscle b-actin.
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PASMC and PA fibroblast proliferation
Pulmonary artery smooth muscle cells (PASMC) and fibroblasts were isolated
from explants of PA from control and pulmonary hypertensive (21 days after
monocrotaline treatment) rats and grown in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% fetal calf serum. PASMC, seeded at 30.000 cell/ml
(approximately 50% confluence) in 96 well plates, were growth arrested by an
exposure for 24 h in 0.1% fetal calf serum (FCS) medium, and then exposed to
quercetin or vehicle (0.1% DMSO) in DMEM containing 10% FCS for 24 or 48 h.
Medium in all experiments using quercetin or vehicle was supplemented with
ascorbic acid (30 mM) to minimize quercetin oxidation. Cell viability and
proliferation were measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) [20] and the 5-bromo-29-deoxyuridine (BrdU)
assays (according to the manufacturer’s protocol, Roche Applied Science),
respectively. Nuclear morphology was assessed after 24 or 48 h of treatment by
incubating the cells with the membrane permeable DNA dye Hoechst 33258
(4 mg/mL) and the membrane impermeable DNA dye propidium iodide (20 mg/
mL) for 40 min at 37 C̊ followed by observation using a fluorescence microscope.
Drugs and reagents
All drugs were from Sigma (Tres Cantos, Spain) except ketamine (Merial, Lyon,
France) and xylazine (KVP Pharma und Veterinar-Produkte GmbH, Kiel,
Germany).
Statistical analysis
Results are expressed as means ¡ SEM of n measurements where n identifies the
number of animals. Statistical analysis was performed by one-way ANOVA
followed by Bonferroni’s post hoc test except for mortality which was assessed
using a Kaplan-Meier analysis and for the PA muscularization study using a x2
test. A value of P,0.05 was considered statistically significant.
Results
Survival, pulmonary artery pressure and right ventricular
hypertrophy
All animals were healthy at baseline. Four out of 35 rats treated with
monocrotaline died within the first three weeks, i.e. before randomization to
quercetin-vehicle (Figure 1A). Only 8 of the 18 monocrotaline-treated rats
assigned to vehicle treatment survived until the end of the experiment and PAP
could only be recorded in 4 of them because the rest died during the anesthesia or
surgery. These latter rats were not included in the mortality analysis but their
organs and tissues were immediately dissected for further use. Four out of 13
monocrotaline treated rats died during the treatment with quercetin. The Kaplan-
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Meier analysis (Figure 1B) shows that quercetin produced a significant increase in
survival.
Monocrotaline produced significant increases in RVSP, RVDP, SPAP, DPAP
and MPAP (Figure 2). Therefore, as expected, monocrotaline treated rats
developed pulmonary hypertension, with MPAP values of 45.2¡7.1 mmHg (vs.
13.6¡0.6 mmHg in controls). An oral daily dose of quercetin starting three weeks
after monocrotaline significantly reduced these parameters (except for RVDP)
Figure 2. Quercetin reduces pulmonary artery pressure. Heart rate (A), right systolic (B) and diastolic (C) ventricular pressure, mean (D), systolic (E) and
diastolic (F) pulmonary arterial pressure. Panels G, H, I show pulmonary artery pressure recordings in the control (Ctrl), monocrotaline (MCT) and
monocrotaline plus quercetin (Quer) group, respectively. Results are means ¡ SEM of 4–9 animals, * indicates P,0.05 versus MCT and #P,0.05, ##
P,0.01 versus Ctrl.
doi:10.1371/journal.pone.0114492.g002
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with MPAP values of 29.7¡5.9 mmHg, which were still significantly above
control values. The heart rate was similar in all experimental groups.
Rats treated with monocrotaline developed a marked right ventricular
hypertrophy as shown by the increased RV weight referred either to the LV+S
weight or to BW (Figure 3A and B). Quercetin significantly reduced both
parameters but again they were still significantly above controls.
Histological changes
Small PA (25–100 mm) observed in lung sections were classified as muscular,
partially muscular and non-muscular arteries (Figures 3C and D). Monocrotaline
increased the percentage of muscular arteries, with a corresponding decrease in
partially muscular and non-muscular arteries. The treatment with quercetin
Figure 3. Quercetin reduces right ventricular hypertrophy and vascular remodeling. (A) Fulton index [RV/(LV+S) ratio]. (B) Right ventricular weight
relative to body weight (RV/BW). (C) Representative images of lung histology. (D) Percentage of muscular, partially muscular and non-muscular arteries in
different groups. For panels A and B each column represents the mean ¡ SEM of 7–9 animals. ** For panel D between 26 and 110 arteries (25–100 mm)
were analyzed in cross-sections of lungs (stained with haematoxylin and eosin) from at least four animals in each group. ** indicates P,0.01 versus
monocrotaline (MCT) and ## indicates P,0.01 versus control (Ctrl).
doi:10.1371/journal.pone.0114492.g003
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resulted in a partial prevention of monocrotaline-induced vascular remodeling
(P,0.01).
KV currents and membrane potential
In freshly isolated PASMC, membrane capacitance, an estimate of membrane
surface, was significantly increased in monocrotaline treated rats. Quercetin was
not able to restore this increase (Figure 4A). Monocrotaline also induced a
significant decrease in the amplitude of the KV currents and membrane
depolarization. Quercetin significantly reversed the inhibition of the KV currents
but it had no significant effect on membrane potential (Figure 4B and 4C).
Gene expression
We examined the gene expression in whole lung homogenates of key proteins
involved in PAH. BMPR2, Kv1.5 and Kv2.1 were strongly downregulated by
monocrotaline (Figure 5). The difference in expression of these genes in the
monocrotaline plus quercetin vs monocrotaline group was not statistically
significant. The expression of survivin and 5HT2A mRNA was significantly
Figure 4. Quercetin prevents the inhibition of KV currents. (A) Cell capacitance (Cm). (B) Current–voltage
relationships measured at the end of the pulse. (C) Membrane potential (Em). * indicates P,0.05 versus
monocrotaline (MCT). # and ## indicate P,0.05 and P,0.01 versus control (Ctrl). Each column or symbol
represents the mean value ¡ SEM (n54–6).
doi:10.1371/journal.pone.0114492.g004
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increased by monocrotaline, and quercetin was able to reverse the latter change.
However, changes in survivin protein (Figure 6) were smaller and not significant
among groups. The mRNA expression of iNOS in whole lung was highly variable
in the monocrotaline group, despite a trend for increased expression in the
monocrotaline group the ANOVA did not yield significant differences. Thus, we
analyzed the mRNA expression of iNOS in homogenates from isolated pulmonary
arteries. In this tissue, iNOS mRNA was significantly increased by monocrotaline
(2.4¡0.7 fold) and this effect was inhibited by quercetin (1.02¡0.6). Despite a
positive trend, the changes in expression of Kv7.1 and Kv7.5 in whole lung were
not statistically different among groups.
Vascular dysfunction
Monocrotaline significantly decreased the maximal relaxation evoked by
acetylcholine in isolated rat pulmonary arteries (Figure 7A) and no changes were
Figure 5. Changes in lung expression of (A) BMPRII, (B) Survivin, (C) 5HT2A, (D) iNOS, (E) Kv1.5, (F) Kv2.1, (G) Kv7.1 and (H) Kv7.5 mRNA by RT-
PCR. Results are means ¡ SEM of 4–8 animals normalized by the expression of b-actin. * indicates P,0.05 versus monocrotaline (MCT), # and ##
P,0.05 and P,0.01 versus control (Ctrl).
doi:10.1371/journal.pone.0114492.g005
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found in rats treated with quercetin. The endothelial dysfunction was
accompanied by a reduction in the expression of eNOS which again was not
reverted by quercetin (Figure 7B). Monocrotaline also produced a significant
hyperresponsiveness of pulmonary arteries to 5-HT (Emax values of 102¡3% of
the response to KCl vs 35¡1% in control) and quercetin again was not able to
prevent it (98¡1%) (Figure 7C).
Figure 6. Changes in the expression of survivin at the level of protein. Lung homogenates were analyzed
by Western blot. Results are means ¡ SEM of 5–8 animals. Protein levels were normalized by the expression
of b-actin.
doi:10.1371/journal.pone.0114492.g006
Figure 7. Quercetin (Quer) does not prevent vascular dysfunction. (A) Relaxant effects of pulmonary arteries to the endothelium-dependent vasodilator
acetylcholine in pulmonary arteries stimulated with phenylephrine. (B) Expression of eNOS mRNA in pulmonary arteries homogenates analyzed by RT-
PCR. (C) Contractile responses to 5-HT in pulmonary arteries expressed as a percent of a previous response to KCl. Results are means ¡ SEM of 4–9
experiments. Results are means ¡ SEM of 4–8 animals normalized by the expression of b-actin. * indicates P,0.05 versus monocrotaline (MCT), # and
## P,0.05 and P,0.01 versus control (Ctrl).
doi:10.1371/journal.pone.0114492.g007
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Expression of MAPK and Akt pathways
Despite an apparent increase in phosphoERK1/2 in some monocrotaline-treated
rats, on average, the phosphorylation of MAP kinases ERK1/2 and p38 was not
significantly different (Figure 8A,B). Pulmonary hypertensive animals showed a
marked increased phosphorylation of Akt (p-Akt to total-Akt ratio), and this
effect was not evident in monocrotaline-quercetin treated animals (Figure 9A).
However, it should be noted that the increased p-Akt/total-Akt ratio was
accompanied by a strong downregulation of Akt. Phosphorylation of S6 at
residues 240–244 was significantly increased by monocrotaline and this effect was
prevented by quercetin (Figure 9B).
Figure 8. Lack of changes in the activation of MAPKs: ERK1/2 and p38MAPK. Lung homogenates were
analyzed by Western blot and probed with the anti-phospho MAPK or the anti-total MAPK antibodies. Results
expressed as phosphorylated forms normalized by the total protein, are means ¡ SEM of 5–8 animals.
doi:10.1371/journal.pone.0114492.g008
Quercetin in Pulmonary Hypertension
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Antiproliferative and pro-apoptotic effects in vitro
PASMC and fibroblasts from monocrotaline-treated rats cultured in the presence
of 10% FCS grew at an exponential rate for 48 h. Addition of quercetin produced
a concentration- and time-dependent decrease in the number of viable cells
estimated by the MTT assay in both cell types (Figure 10A and 10B). We analyzed
whether quercetin was reducing cell proliferation in PASMC from monocrotaline-
treated rats by the analysis of BrdU incorporation. Quercetin produced significant
inhibitory effects on BrdU incorporation at 24 h (Figure 10C).
Figure 9. Changes in the PI3K/Akt/mTOR/S6 signaling pathway. Lung homogenates were analyzed by
Western blot and probed with the anti-phospho Akt, the anti-total Akt or anti-b actin (A) or antiphospho S6
ribosomal protein (serines 240, 244) or total S6 (B) antibodies. Results expressed as phosphorylated forms
normalized by the total protein, are means ¡ SEM of 5–8 animals. * indicates P,0.05 versus monocrotaline
(MCT), #, ## indicate P,0.05, and P,0.0001 versus control (Ctrl).
doi:10.1371/journal.pone.0114492.g009
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In PASMC from control rats, proliferation, measured by the MTT assay (not
shown) or BrdU incorporation was also inhibited (Figure 11). It also strongly
reduced the total number of cells (positive for the membrane permeable dye
Hoescht 33258) and produced an increase in non viable cells (positive for the
membrane impermeable dye propidium iodide, Figure 11). Non viable cells
showed chromatin condensation and nuclear fragmentation characteristic of
apoptotic cells.
Discussion
PAH is characterized by increased pulmonary artery pressure as a result of
increased pulmonary vascular resistance due to pulmonary vascular vasocon-
striction, increased smooth muscle cell proliferation/apoptosis ratio and in situ
thrombosis [3]. Quercetin has shown a number of vascular effects including
vasodilator, antiplatelet, smooth muscle antiproliferative and pro-apoptotic
effects in the systemic and coronary circulation. Herein we show that quercetin is
also partially protective in a model of PAH by lowering PAP, RVH and vascular
remodeling. In addition, in vitro quercetin exerted pulmonary vasodilator effects
and inhibited cell proliferation in PASMCs.
PAH develops progressively and most PAH patients with earlier-stage disease
such as New York Heart Association (NYHA) class I or II are asymptomatic and
the condition is not identified until symptoms become severe [1]. Therefore,
treatments for PAH must be effective once the symptoms have developed. Gao
et al. have recently reported that a high dose of quercetin (10 fold the one we
used) from day 2 to day 21 after monocrotaline and analyzing the results at day
Figure 10. Quercetin decreases PASMC and fibroblast proliferation. (A) PASMC and (B) fibroblasts were isolated from monocrotaline-treated rats and
grown in culture. Viable cells were estimated by the MTT test exposed to quercetin in culture for 24 or 48 h. (C) PASMC proliferation was analyzed by the
BrdU incorporation after 24 h of treatment with increasing concentrations of quercetin. Results are means ¡ SEM of 3–4 experiments performed in
triplicate. ** indicates P,0.01 versus vehicle (DMSO).
doi:10.1371/journal.pone.0114492.g010
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41st, i.e. a preventive strategy, produced a reduction of PAP and RVH but they did
not attempt to analyze the mechanisms involved [21]. We chose to start treatment
with quercetin 21 days after monocrotaline. At this stage, the animals develop
marked increases in PAP and the severity of the disease in our study was
evidenced by 11% mortality. The final mortality in untreated animals was 56%
(78% including animals which died during anesthesia or surgery). Moreover,
surviving rats were in better hemodynamic conditions when treated by quercetin.
As expected by the reduced right ventricular afterload, quercetin also decreased
the right ventricular hypertrophy. The effectiveness of quercetin in this
experiment with a very aggressive form of PAH suggests that it might prevent
premature death in humans with PAH. It should be noted, however, that although
all clinically useful drugs for PAH are effective in this animal model, not all drugs
reversing monocrotaline-induced increased PAP are effective in clinical PAH [22].
Despite the increased survival and the hemodynamic, anatomical and
histological improvement, most of the conventional markers of PAH such as
membrane depolarization, endothelial dysfunction and downregulation of
BMPR2 and KV1.5, were unaffected or modestly affected by quercetin. Endothelial
dysfunction was accompanied by a reduced the expression of eNOS. This is
consistent with previous studies showing that eNOS and other endothelial cell
markers, such as caveolin-1 or CD31, are downregulated, suggesting that
Figure 11. Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from
control rats. (A) PASMC proliferation was analyzed by the BrdU incorporation after 24 h of treatment with
increasing concentrations of quercetin. Results are means ¡ SEM of 4–5 experiments. (B) Photographs of
PASMC after 48 h treatment with quercetin in culture stained with the membrane permeable blue dye Hoescht
33258 (left, viable and non-viable cells) and with the membrane impermeable red dye propidium iodide (right,
non-viable cells). (C) Magnified photographs of cells treated with 10 mM quercetin showing three apoptotic
cells (top and middle cells) with chromatin condensation and nuclear fragmentation and two healthy cells
(bottom).
doi:10.1371/journal.pone.0114492.g011
Quercetin in Pulmonary Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0114492 December 2, 2014 15 / 20
monocrotaline causes disruption of the integrity of the endothelial cells [23, 24].
Quercetin has demonstrated to improve endothelial function in several models of
cardiovascular disease via decreased expression of NADPH oxidase subunits,
restoring eNOS uncoupling, eNOS phosphorylation or scavenging superoxide
[25]. However, quercetin was unable to restore eNOS downregulation which
appears to be a major contributor to endothelial dysfunction in this model. In
fact, a trend for reduced eNOS expression was found in quercetin-treated animals
which is in agreement with in vitro data in human umbilical endothelial cells or in
spontaneously hypertensive rats [26, 27]. Notably, quercetin inhibited the decrease
in KV currents and the overexpression of 5-HT2A and iNOS induced by
monocrotaline. Downregulated 5-HT2A receptors might contribute to reduce
arterial remodeling [28] but it was not sufficient to decrease the vascular
hyperresponsiveness to 5-HT. This later effect is probably related to changes in
reactive oxygen species and cyclooxygenase activity as observed in other models of
PAH as it can be normalized by cyclooxygenase inhibitors and antioxidants
[29, 30, 31]. The fact that quercetin inhibits the changes in specific genes but does
not affect other genes may reflect that changes in gene expression in this model of
PAH operate through quercetin-sensitive and -insensitive signaling pathways.
Proliferation of PAMSC leading to increased muscularization of small PA and
reduced vascular lumen is considered the hallmark of the most advanced and
aggressive forms of PAH. Quercetin reduced the number of muscular arteries, an
effect that is likely to contribute to the decrease in PAP. In order to confirm the
in vivo findings, we tested the effects of quercetin on PASMC in vitro. We found
that quercetin produced a concentration-dependent decrease in cell number of
PASMC and fibroblasts, related to the inhibition of proliferation, as measured by
the BrdU incorporation. However, quercetin also induces apoptosis in vascular
smooth muscle [20] which may also marginally contribute to reduce cell viability
in these in vitro experiments.
A large number of cell signaling pathways may be affected by quercetin. In fact,
quercetin is a broad-spectrum protein kinase inhibitor being a competitive and
reversible ligand for the ATP binding site [32]. However, few studies have
confirmed it in its in vivo effects. Therefore, we analyzed in the rat lungs from the
in vivo study the signaling pathways reported to be involved in the pathophy-
siology of PAH which could be potentially targeted by quercetin. These include
those activated by platelet derived growth factor (PDGF) and transforming
growth factor-b (TGF-b): MAPKs, the PI3K- Akt-mTor pathway, and the
antiapoptotic protein survivin.
Quercetin is a canonical pan-inhibitor of MAPKs and the TGF-b pathway [33]
and previous studies on the effects of quercetin on vascular smooth muscle cell
viability, migration, and proliferation have related their findings to interactions
with MAPKs [20, 34, 35]. MAPKs (e.g. ERK1/2, p38MAPK and JNK) play a key
role in cell proliferation and this axis has been suggested as a potential therapeutic
target in PAH [6]. However, their role in PAH induced by monocrotaline is
controversial. In fact, increased [36], unchanged [37] or decreased [38]
phosphorylation of p38MAPK and unchanged [36, 37] or increased [6]
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phosphorylation of ERK1/2 have been reported. We found no significant changes
among groups in p38MAPK and ERK1/2 phosphorylation suggesting that MAPKs
play little role in the PAH and in the effects of quercetin in this model.
Another potential pathway for PAMSC muscularization in PAH is via
overexpression of the antiapoptotic protein survivin. In fact, genetic targeting of
survivin has been shown to reduce PAH in the monocrotaline-treated rats [39].
We found that survivin mRNA was significantly overexpressed in the lungs of
monocrotaline-treated rats but the protein increase did not achieve statistical
significance. This difference might be due to post-transductional changes.
Interestingly, quercetin has been shown to induce survivin downregulation in
several cancer cells, via decreasing the survivin promoter activity [40]. Herein we
show that chronic quercetin had no clear effect on survivin expression, suggesting
that in vivo the downregulation of survivin is not a major mechanism for the
antiproliferative effect. This is consistent with the high concentrations (50 mM) of
quercetin required to downregulate survivin [40].
The intracellular signaling pathway involving the PI3K/Akt/mTOR/S6 plays an
important role in cell proliferation in PAH and it is thought to be a promising
therapeutic target for this syndrome [41, 42, 43]. Quercetin may interfere with the
activity of both PI3K and mTOR [44, 45]. We found that Akt phosphorylation
was increased by monocrotaline which was associated by a strong downregulation
of Akt expression. As previously reported in other cell types [45, 46], the Akt
phosphorylation was diminished by quercetin, suggesting that inhibition of this
pathway may be involved in the decreased PA muscularization. This is consistent
with the high potency of quercetin to inhibit PI3K (KD at submicromolar
concentrations) [32]. Furthermore, we also found that phosphorylation of S6, the
downstream target of mTOR, was higher in the group treated with monocrotaline
and this increase was inhibited by quercetin.
Quercetin is also a well-known vasodilator [13, 18]. We also found that
quercetin was similarly effective in isolated PA both from control and
monocrotaline-treated rats stimulated by the thromboxane A2 mimetic U46619
(2logIC50 of 5.3 and 5.1, respectively, not shown). Thus, this vasodilator effect
may be an additional contributor to the reduction in PA pressure in this model.
The pharmacokinetics of quercetin are complex. It is not present in the blood in
its free form but circulates conjugated with glucuronide which is released in the
tissues after deconjugation [47]. Because quercetin was not administered the day
of the end-point measurements, it is likely that the effects observed reflect the
chronic rather than the acute actions of quercetin and the reduction in PA
pressure may be underestimated.
In conclusion, quercetin is partially protective in this rat model of PAH. It
delayed mortality by lowering PAP, RVH and vascular remodeling. Quercetin
exerted effective vasodilator effects in isolated PA, inhibited cell proliferation and
induced apoptosis in PASMCs. These effects were associated with decreased 5-
HT2A receptor expression and Akt and S6 phosphorylation and partially restored
Kv currents. Therefore, quercetin could be useful in the treatment of PAH.
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